Contemporary diagnostic and management techniques for extraesophageal reflux disease

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 12, Issue 6, 2004, Pages 519-524

  Meyer, Tanya K ^a   Olsen, Eric ^a   Merati, Albert ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Dual pH probe; Extraesophageal reflux; Impedance; Laryngology; Laryngopharyngeal reflux

Indexed keywords

ACID; ALGINIC ACID; ANTIHISTAMINIC AGENT; BACLOFEN; BENATOPRAZOLE; BICARBONATE; CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE AGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; POTASSIUM DERIVATIVE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SEROTONIN AGONIST; SUCRALFATE;

ANAMNESIS; CELL PROTECTION; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; ESOPHAGUS DISEASE; ESOPHAGUS MOTILITY; EXTRAESOPHAGEAL REFLUX; GAS; HUMAN; INCIDENCE; LAPAROSCOPY; LARYNGOSCOPY; LIQUID; LOWER ESOPHAGUS SPHINCTER; MEAL; MONITORING; PH MEASUREMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; RELIABILITY; REPRODUCIBILITY; REVIEW; SCORING SYSTEM; SIDE EFFECT; SOLID; STANDARDIZATION; STOMACH FUNDOPLICATION; TREATMENT OUTCOME;

BACLOFEN; CHILD; ENDOSCOPY, GASTROINTESTINAL; GASTROESOPHAGEAL REFLUX; HUMANS; MUSCLE RELAXANTS, CENTRAL; PROTON PUMPS;

EID: 9444242040     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moo.0000144390.95132.9b     Document Type: Review

References (47)

1. Koufman JA, Aviv JE, Casiano RR, Shaw GY: Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg 2002, 127:32-35. This is an excellent review of the topic from an otolaryngology standpoint. It features a tremendous reference list. Particularly good to clarify terminology and nomenclature of these disorders.
2. Belafsky PC, Postma GN, Koufman JA: Validity and reliability of the reflux symptom index (RSI). J Voice 2002, 16:274-277.
3. Powitzky ES, Khaitan L, Garrett CG, et al.: Symptoms, quality of life, videolaryngoscopy, and twenty-four-hour triple-probe pH monitoring in patients with typical and extraesophageal reflux. Ann Otol Rhinol Laryngol 2003, 112: 859-865. A well-executed study with additional information regarding quality-of-life data.
4. First multi-disciplinary international symposium on supraesophageal complications of gastroesophageal reflux disease. Workshop consensus reports. Am J Med 1997, 103:149S-150S.
5. Bilgen C, Ogut F, Kesimli-Dinc H, et al.: The comparison of an empiric proton pump inhibitor trial vs 24-hour double-probe Ph monitoring in laryngopharyngeal reflux. J Laryngol Otol 2003, 117:386-390.
6. Bautista J, Fullerton H, Briseno M, et al.: The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain-a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2004, 19:1123-1130.
7. Hicks DM, Ours TM, Abelson TI, et al.: The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice 2002, 16:564-579. An important but controversial paper wherein normal volunteers underwent laryngoscopy. Many detractors of the importance of laryngoscopic findings in reflux cite this article for its high rate of "findings" in normals. Closer reading reveals important differences aside from interarytenoid swelling that must be noted in these patients.
8. Belafsky PC, Postma GN, Koufman JA: The validity and reliability of the reflux finding score (RFS). Laryngoscope 2001, 111:1313-1317.
9. Beaver ME, Stasney CR, Weitzel E, et al.: Diagnosis of laryngopharyngeal reflux disease with digital imaging. Otolaryngol Head Neck Surg 2003, 128:103-108.
10. Williams RB, Szczesniak MM, Maclean JC, et al.: Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis. Am J Gastroenterol 2004, 99:777-785.
11. Koufman JA: The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991, 101(4 Pt 2 suppl 53):1-78. The classic reference that ignited our fields' interest in this clinical issue.
12. Maldonado A, Diederich L, Castell DO, et al.: Laryngopharyngeal reflux identified using a new catheter design: defining normal values and excluding artifacts. Laryngoscope 2003, 113:349-355.
13. Katz PO: Ambulatory esophageal and hypopharyngeal pH monitoring in patients with hoarseness. Am J Gastroenterol 1990, 85:38-40.
14. Smit CF, Tan J, Devriese PP, et al.: Ambulatory pH measurements at the upper esophageal sphincter. Laryngoscope 1998, 108:299-302.
15. Johnson PE, Koufman JA, Nowak LJ, et al.: Ambulatory 24-hour double-probe pH monitoring: the importance of manometry. Laryngoscope 2001, 111:1970-1975.
16. Postma GN, Belafsky PC, Aviv JE, Koufman JA: Laryngopharyngeal reflux testing. Ear Nose Throat J 2002, 81 (9 suppl 2):14-18.
17. Ulualp SO, Toohill RJ, Hoffmann R, Shaker R: Pharyngeal pH monitoring in patients with posterior laryngitis. Otolaryngol Head Neck Surg 1999, 120: 672-677.
18. Bove M, Ruth M, Cange L, Mansson I: 24-H pharyngeal pH monitoring in healthy volunteers: a normative study. Scand J Gastroenterol 2000, 35:234-241. Important study providing baseline/normal data for upper probe findings.
19. Wenzl TG, Moroder C, Trachterna M, et al.: Esophageal pH monitoring and impedance measurement: a comparison of two diagnostic tests for gastroesophageal reflux. J Pediatr Gastroenterol Nutr 2002, 34:519-523. A good reference comparing pH and impedance techniques.
20. Balaji NS, Blom D, DeMeester TR, Peters JH: Redefining gastroesophageal reflux (GER). Surg Endosc 2003, 17:1380-1385.
21. Postma GN, Bach KK, Belafsky PC, Koufman JA: The role of transnasal esophagoscopy in head and neck oncology. Laryngoscope 2002, 112: 2242-2243.
22. Koufman JA, Belafsky PC, Bach KK, et al.: Prevalence of esophagitis in patients with pH-documented laryngopharyngeal reflux. Laryngoscope 2002, 112:1606-1609.
23. Aviv JE, Takoudes TG, Ma G, Close LG: Office-based esophagoscopy: a preliminary report. Otolaryngol Head Neck Surg 2001, 125:170-175. One of the leaders in re-introducing esophagoscopy back into otolaryngology, where the field had dominated decades ago.
24. Halkiewicz F, Kasner J, Karczewska K, Rusek-Zychma M: Ultrasound picture of gastroesophageal junction in children with reflux disease. Med Sci Monit 2000, 6:96-99.
25. Bowrey DJ, Williams GT, Clark GW: Histological changes in the oesophageal squamous mucosa: correlation with ambulatory 24 hour pH monitoring. J Clin Pathol 2003, 56:205-208.
26. Cury EK, Schraibman V, Faintuch S: Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children-discussion on daily practice. J Pediatr Surg 2004, 39:e4-e7.
27. Steiner SJ, Gupta SK, Croffie JM, Fitzgerald JF: Correlation between number of eosinophils and reflux index on same day esophageal biopsy and 24 hour esophageal pH monitoring. Am J Gastroenterol 2004, 99:801-805.
28. Krishnan U, Mitchell JD, Tobias V, et al.: Fat laden macrophages in tracheal aspirates as a marker of reflux aspiration: a negative report. J Pediatr Gastroenterol Nutr 2002, 35:309-313.
29. Ding Y, Simpson PM, Schellhase DE, et al.: Limited reliability of lipid-laden macrophage index restricts its use as a test for pulmonary aspiration: comparison with a simple semiquantitative assay. Pediatr Dev Pathol 2002, 5:551-558.
30. Katz PO: Optimizing medical therapy for gastroesophageal reflux disease state of the art. Rev Gastroenterol Disord 2003, 3:59-69.
31. Xue S, Katz PO, Banerjee P, et al.: Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001, 15:1351-1356. Describes the basis of nighttime H2 blockers in reflux patients. The original papers from this group had previously described the benefit of H2 blocker compared to additional PPI therapy above BID dosing in normals.
32. Hellstrom PM, Vitols S: The choice of proton pump inhibitor: Does it matter? Pharmacol Toxicol 2004, 94:106-111.
33. Holtmann G, Bytzer P, Metz M, et al.: A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastrooesophageal reflux disease. Aliment Pharmacol Ther 2002, 16:479-485.
34. Miner P Jr, Katz PO, Chen Y, Sostek M: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003, 98:2616-2620. Study demonstrated that esomeprazole controlled pH for a longer time than the other four PPIs. This study was funded by AstraZeneca.
35. Galmiche JP, Bruley Des Varannes S, Ducrotte P, et al.: Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004, 19:655-662.
36. El-Serag HB, Lee P, Buchner A, et al.: Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol 2001, 96:979-983. One of the better-controlled studies in this area, which selected out of this specific group of patients from EER or GER patients in general.
37. Dekel R, Morse C, Fass R: The role of proton pump inhibitors in gastrooesophageal reflux disease. Drugs 2004, 64:277-295.
38. Vela MF, Tutuian R, Katz PO, Castell DO: Baclofen decreases acid and nor-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003, 17:243-251.
39. Ciccaglione AF, Marzio L: Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003, 52:464-470.
40. Smoak BR, Koufman JA: Effects of gum chewing on pharyngeal and esophageal pH. Ann Otol Rhinol Laryngol 2001, 110:1117-1119.
41. Tonini M, De Giorgio R, De Ponti F: Progress with novel pharmacological strategies for gastro-oesophageal reflux disease. Drugs 2004, 64:347-361.
42. Vakil N: Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004, 19:1041-1049.
43. Lindstrom DR, Wallace J, Loehrl TA, et al.: Nissen fundoplication surgery for extraesophageal manifestations of gastroesophageal reflux (EER). Laryngoscope 2002, 112:1762-1765.
44. Oelschlager BK, Eubanks TR, Oleynikov D, et al.: Symptomatic and physiologic outcomes after operative treatment for extraesophageal reflux. Surg Endosc 2002, 16:1032-1036.
45. Freston JW, Triadafilopoulos G: Review article: approaches to the long-term management of adults with GERD-proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy? Aliment Pharmacol Ther 2004, 19(suppl 1):35-42.
46. Hogan WJ, Shaker R: A critical review of endoscopic therapy for gastroesophageal reflux disease. Am J Med 2003, 115(suppl 3A):201S-210S. Excellent review of endoscopic therapy. Because of the rapidly progressing nature of the technology, future review articles may be more timely.
47. Oelschlager BK, Eubanks TR, Mironian N, et al.: Laryngoscopy and pharyngeal pH are complementary in the diagnosis of gastroesophageal-laryngeal reflux. J Gastrointest Surg 2002, 6:189-194.